Next Article in Journal
Free Radical Scavenging and Cellular Antioxidant Properties of Astaxanthin
Next Article in Special Issue
Aquaporins in Salivary Glands: From Basic Research to Clinical Applications
Previous Article in Journal
Iron in Multiple Sclerosis and Its Noninvasive Imaging with Quantitative Susceptibility Mapping
Article Menu
Issue 1 (January) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2016, 17(1), 105; doi:10.3390/ijms17010105

Urine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart Failure

1
Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, University of Tokyo, Tokyo 113-8655, Japan
2
Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan
*
Author to whom correspondence should be addressed.
Academic Editor: Kenichi Ishibashi
Received: 19 December 2015 / Revised: 7 January 2016 / Accepted: 11 January 2016 / Published: 14 January 2016
(This article belongs to the Special Issue Aquaporin)
View Full-Text   |   Download PDF [486 KB, uploaded 14 January 2016]   |  

Abstract

Aquaporin-2, a member of the aquaporin family, is an arginine vasopressin-regulated water channel expressed in the renal collecting duct, and a promising marker of the concentrating and diluting ability of the kidney. The arginine vasopressin type-2 antagonist, tolvaptan, is a new-generation diuretic; it is especially indicated in patients with decompensated heart failure refractory to conventional diuretics. However, the ideal responders to tolvaptan have not yet been identified, and non-responders experience worse clinical courses despite treatment with tolvaptan. Urine aquaporin-2 has recently been demonstrated as a promising predictor of response to tolvaptan. We here validated aquaporin-2-guided tolvaptan therapy in patients with decompensated heart failure. Long-term efficacy of tolvaptan treatment in the responders defined by aquaporin-2 needs to be validated in the future prospective study. View Full-Text
Keywords: heart failure; congestion; chronic kidney disease; hyponatremia heart failure; congestion; chronic kidney disease; hyponatremia
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Imamura, T.; Kinugawa, K. Urine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart Failure. Int. J. Mol. Sci. 2016, 17, 105.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top